ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-OR035

Treatment with Dipeptidyl-Peptidase Inhibitors (DPP4_Rx) Delays Progression of Kidney Disease and Reduces Mortality

Session Information

Category: Diabetic Kidney Disease

  • 602 Diabetic Kidney Disease: Clinical

Authors

  • Garcia-Touza, Mariana, Kansas City VA Medical Center, Kansas City, Missouri, United States
  • Wiegmann, Thomas, Kansas City VA Medical Center, Kansas City, Missouri, United States
  • Oni, Olurinde, Kansas City VA Medical Center, Kansas City, Missouri, United States
  • Wiegmann, Peter Sigurd, Midwest Biomedical Research Foundation, Kansas City, Missouri, United States
  • Goel, Archana, Kansas City VA Medical Center, Kansas City, Missouri, United States
  • Sharma, Mukut, Kansas City VA Medical Center, Kansas City, Missouri, United States
  • Sharma, Ram, Kansas City VA Medical Center, Kansas City, Missouri, United States
  • Gomes, Maria N., Kansas City VA Medical Center, Kansas City, Missouri, United States
  • Savin, Virginia J., Kansas City VA Medical Center, Kansas City, Missouri, United States

Group or Team Name

  • Cardiovascular and Renal Clinical Research at MidWest BioMedical Research Foundation
Background

Effects of DPP4_Rx on cardiovascular morbidity are disputed and effects on renal function are not known.

Methods

Data from a large cohort of veterans diagnosed with type 2 diabetes mellitus (T2DM) were used to identify patients on DPP4_Rx (group 1). and without DPP4_Rx (group 2). Groups were matched for age (yrs), sex, BMI, initial renal function, follow-up time (FU, minimum 365 days). Propensity score matching (PSM) was used to adjust groups 1 and 2 with a best odds ratio about 1:2. Groups were compared to determine the effect of DPP4_Rx on the progression of CKD and all-cause mortality. Increase in serum creatinine (creat, mg/dl) over time (days) was taken as a measure of progression of CKD. Data were extracted using the Veterans Administration Informatics and Computing Infrastructure (VINCI), and analyzed using SPSS and SAS. Results were compared using t-tests, frequency tables, Kaplan Meier survival curves, hazard ratios (HR) and p values.

Results

Results show that subjects in group 1 (N=20,424) had baseline variables (creat 1.061, FU 1117, age 68.2 yrs and BMI 31.9) similar to Group 2 (N=52,118, creat 1.09, FU 1197, age 69.9, BMI 31.7). DM control improved in group 1 (HgbA1c 8.3% to 7.9%, p < 0.001) but remained worse than group 2 (7.2% to 7.1%) A significant reduction in progression of CKD was seen in group 1. The proportion of patients exceeding creat of 1.5, 3, and 6 mg/dl was reduced by 6.5, 40.8 and 47.4%, all p<0.01 respectively. Time to ESRD (creat >6.0 mg/dl) was delayed also by 143.7 days p < 0.01. Mortality from all causes was reduced by 78.1%, but time to death was not changed.

Conclusion

We conclude that DPP4_Rx associates with a significant reduction in frequency of all-cause mortality and progression toward ESRD independent of glucose control. The data are consistent with a reduction in the number and severity of discrete morbid events that would associate with progressive renal disease and all cause mortality..

Funding

  • Veterans Affairs Support